5 ICS在儿童哮喘长期维持治疗中应用 已通过.pptxVIP

ICS在儿童哮喘长期维持治疗中的应用;1 中华医学会儿科学分会呼吸学组, 等. 儿童支气管哮喘诊断与防治指南.中华儿科杂志, 2008, 46(10): 745-753. 2 Rank MA, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol, 2013,131(3):724-9. 3 Castro-Rodriguez GA, et al. The role of inhaled corticosteroids and montelukast in children with mild–moderate asthma: results of a systematic review with meta-analysis. Arch Dis Child, 2010,95:365–370. 4 Szefler SJ, et al. Budesonide inhalation suspension versus montelukast in children aged 2 to 4 years with mild persistent asthma. J Allergy Clin Immunol: In Practice, 2013,1:58-64。 5 McLaughlin T, et al. Risk of recurrent emergency department visits or hospitalizations in children with asthma receiving nebulized budesonide inhalation suspension compared with other asthma medications. Current Medical Research and Opinion, 2007, 23(6): 1319–1328. 6 GINA. 2012: 40. 7 Brand PL. Inhaled corticosteroids should be the first line of treatment for children with asthma. Padiatric Respiratory Reviews, 2011,12: 245–249. 8申昆玲, 等. 糖皮质激素雾化吸入疗法在儿科应用的专家共识. 临床儿科杂志, 2011, 29(1): 86-91. 9 Kemp JP, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol, 1999, 83: 231–239. 10 Baker JW, et al. A Multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics, 1999, 103 (2): 414-421.;达到并维持症状的控制 维持正常活动，包括运动能力 使肺功能水平尽量接近正常 预防哮喘急性发作 避免因哮喘药物治疗导致的不良反应 预防哮喘导致的死亡;长期、持续、规范、个体化治疗 快速缓解症状 防止症状加重和预防复发;1 中华医学会儿科学分会呼吸学组, 等. 儿童支气管哮喘诊断与防治指南.中华儿科杂志, 2008, 46(10): 745-753. 2 Rank MA, et al. The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol, 2013,131(3):724-9. 3 Castro-Rodriguez GA,